Of the 20 authors, five were drug company employees. Three others received consulting fees from Eli Lilly, Biogen, and Eisai ... with the Use of NIH Names and Logo policy.” ...

In a report released today, George Farmer from Scotiabank maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...

Mizuho Securities analyst Salim Syed maintained a Buy rating on Biogen (BIIB – Research Report) yesterday and set a price target of $207.00.

Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...

In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet ...

Stoke Therapeutics Inc. (Nasdaq: STOK) has pulled in Biogen (Nasdaq: BIIB) to help it develop and commercialize a treatment ...

While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...

Investors fled the company's stock in 2024 as a slow US launch of Leqembi, the Alzheimer's disease drug it sells with Japan's ...

(Reuters) -Sage Therapeutics said on Monday that its board has unanimously rejected Biogen’s $469 million offer, stating it "significantly undervalues" the company and does not serve ...

Biogen stock opened at $137.33 on Thursday. The company’s 50-day moving average price is $147.31 and its 200-day moving average price is $173.80. Biogen has a twelve month low of $128.51 and a ...

stating it "significantly undervalues" the company and does not serve shareholders' best interests. Biogen, which currently holds a 10.2% stake in Sage, proposed to acquire all outstanding Sage ...

The only other time Biogen stock has spiked was in September 2022, when, alongside Japanese Pharma Eisai, its development partner in the Alzheimer's treatment field, the company shared data from a ...